Introduction {#s1}
============

The influenza A virus genome is composed of eight single-stranded viral RNA (vRNA) segments of negative polarity that form viral ribonucleoprotein (vRNP) complexes with viral RNA-dependent RNA polymerases (vRdRPs) and nucleocapsid proteins (NPs). Both transcription and replication of vRNA are catalyzed by vRdRPs consisting of three viral proteins: PB1, PB2, and PA. Transcription of the influenza virus genome is initiated in a primer-dependent manner. The cap-1 structure of cellular mRNA was recognized by PB2 ([@bib12]), and the capped RNA is cleaved 10--15 bases downstream of the 5\'-terminus by the endonuclease activity of PA ([@bib9]; [@bib57]). This cleaved, short RNA with a 5'-cap structure serves as a primer for the initiation of transcription. After elongation of the nascent RNA chain, transcription is terminated by a virus-specific polyadenylation mechanism ([@bib42]): vRdRP reaches the poly(U) stretch of the vRNA template adjacent to its 5\'-end and is thought to slip there repeatedly, leading to the addition of a poly(A) tail at the 3\'-end of the nascent viral RNA transcript. Replication of the viral genomic RNA takes place in a primer-independent manner and proceeds in two steps: in the first step, vRdRP synthesizes full-length RNA copies of positive polarity, termed complementary RNA (cRNA); and in the second step, progeny vRNAs are amplified from the cRNA template. Both cRNA and vRNA products from each replication step contain a 5\'-triphosphate end group ([@bib14]; [@bib56]), indicating that both replications are initiated de novo.

vRdRP and the viral RNA template are minimal and essential viral factors for viral RNA synthesis ([@bib6]; [@bib24]). NP is thought to play roles in efficient RNA elongation ([@bib15]) and regulation of vRdRP activity for replication ([@bib2]; [@bib36]; [@bib43]; [@bib50]). These observations, which were provided using mainly cell-free systems, concord with the fact that an in vivo viral mini-genome replicon system can be reconstituted by transfection of expression plasmids for PB1, PB2, PA, and NP and of a plasmid for vRNA driven by cellular RNA polymerase I ([@bib40]). These viral factors catalyze cell-free viral RNA synthesis, but at a limited level. Furthermore, cell-free viral replication activity using viral factors could be observed in the presence of a large amount of viral factors ([@bib54]). In early cell-free studies using nuclei or nuclear extracts (NEs) prepared from infected cells, a robust level of transcription took place and replication to some extent could be observed ([@bib1]; [@bib17]; [@bib34]). Dissection and reconstitution of a cell-free viral RNA synthesis system using vRNP complexes isolated from virions, an exogenously added model RNA template, and uninfected NEs indicated that host-derived factors could be involved in the process of viral RNA synthesis ([@bib51]). Using this assay system, we identified two stimulatory host factors, designated as RNA polymerase activating factors (RAF) -I and -II, which were identified as Hsp90 and UAP56/BAT1, respectively ([@bib31]; [@bib32]). Later, we found a factor, designated as influenza virus replication factor (IREF)-1, which upregulates unprimed cRNA synthesis from vRNA by the vRNP complex through promotion of the promoter clearance step and avoidance of premature abortive RNA synthesis. IREF-1 was shown to be identical to the minichromosome maintenance (MCM) complex ([@bib20]). Recently, several screening studies including high-throughput screenings have indicated that there may be more candidates for the host factors that affect viral RNA synthesis ([@bib4]; [@bib13]; [@bib18]; [@bib23]; [@bib35]; [@bib55]). Among these potentially relevant candidates, some were further examined and characterized using in vivo and/or cell-free analyses.

Here, we focused our study on identification of a novel host factor(s) that facilitates the efficient second step of replication, that is, vRNA synthesis from the cRNA template. We found that a crude fraction of uninfected NE enables vRdRP to synthesize unprimed vRNA from the cRNA template effectively, and we thus designated the novel factor(s) responsible for this activity as IREF-2. Further fractionation and purification identified two host-derived factors, pp32 and APRIL. The target of these factors was shown to be a free form of the vRdRP trimeric complex. IREF-2 was found to preferentially upregulate vRNA synthesis rather than cRNA synthesis. Knockdown (KD) of IREF-2 using short interfering dsRNA resulted in decreased levels of viral RNA in the infected cells. However, the primary transcription from the incoming vRNP complexes was not affected. These results suggest that IREF-2 functions as a host factor for vRNA synthesis from cRNA in infected cells.

Results {#s2}
=======

Purification of IREF-2 from NEs of uninfected cells {#s2-1}
---------------------------------------------------

To establish a cell-free viral RNA synthesis system that mimics the second replication step, that is, unprimed vRNA synthesis from a cRNA template, we used micrococcal nuclease-treated vRNP complexes (mnRNP) as an enzyme source and the 53 nucleotide (nt)-long RNA harboring both terminal sequences of cRNA derived from segment 8 (designed 'c53') as an exogenous cRNA model template ([@bib51]). This enzyme source was established in an early study ([@bib47]) and well characterized in subsequent studies ([@bib11]; [@bib47]). These previous studies showed that mnRNP does not support unprimed vRNA synthesis from the cRNA template. NEs prepared from uninfected cells were fractionated through a phosphocellulose column by stepwise elution with increasing concentrations of KCl. P0.05 was a fraction unbound to the column, whereas P0.2, P0.5, and P1.0 were fractions eluted using 0.2 M, 0.5 M, and 1.0 M salt solutions, respectively. These fractions were examined individually in terms of their ability to promote cell-free vRNA synthesis reaction in the absence of any primer ([Figure 1A](#fig1){ref-type="fig"}, lanes 3--6). The 53 nt-long RNA product was formed only in the presence of the P0.05 fraction (lane 3). The RNA synthesis was dependent on the mnRNP, c53, and P0.05 fractions ([Figure 1A](#fig1){ref-type="fig"}, lanes 8--10). This novel activity present in the P0.05 fraction was designated as IREF-2. Next, we tried to purify and identify the factor responsible for the IREF-2 activity in the P0.05 fraction through fractionation using sequential column chromatography ([Figure 1B](#fig1){ref-type="fig"}). To determine fractions containing the IREF-2 activity at each column chromatography step, every fraction was individually assayed for RNA synthesis ability in the presence of mnRNP and the c53 model template, but in the absence of any added primer. On the basis of its chromatographic behavior, IREF-2 appears to be highly acidic. At the final purification step using an anion exchanger (the Mono-Q column), the IREF-2 activity was recovered in fractions eluted with about 500 mM of KCl (fraction numbers 6--10 in [Figure 1C](#fig1){ref-type="fig"}, upper panel). The fractions from the Mono-Q column were also analyzed by SDS-PAGE followed by silver staining ([Figure 1C](#fig1){ref-type="fig"}, lower panel). Comparison of the polypeptide elution patterns and the level of the IREF-2 activity strongly suggested that two polypeptides with molecular masses of approximately 32 and 31 kDa corresponded to the IREF-2 activity ([Figure 1C](#fig1){ref-type="fig"}, arrows). The 32- and 31-kDa polypeptides were designated IREF-2α and β, respectively.10.7554/eLife.08939.003Figure 1.Purification of influenza virus replication factor-2 (IREF-2).(**A**) IREF-2 activity in uninfected nuclear extracts (NEs). Biochemical complementation assays using a cell-free vRNA replication system for fractions separated by phosphocellulose column chromatography were performed. The fractions, P0.05 (lane 3), P0.2 (lane 4), P0.5 (lane 5), and P1.0 (lane 6), were individually assayed in the cell-free viral RNA synthesis reaction employing 5 ng PB1-equivalent micrococcal nuclease-treated vRNP (mnRNP) as an enzyme source and 10 ng of the complementary RNA (cRNA) model template (c53), as described in the \'Materials and methods\'. Dinucleotide ApG, serving as primer for viral RNA synthesis, was added to a final concentration of 0.2 mM (lane 1). To confirm the components required for the reactions, cell-free viral RNA synthesis with mnRNP and c53 in the presence of the P0.05 fraction was carried out (lane 7; identical to the conditions of lane 3). Simultaneously, reactions omitting the cRNA model template (lane 8), mnRNP (lane 9), or P0.05 fraction (lane 10; identical to the conditions of lane 2) were also carried out. After incubation at 30°C for 2 hr, each reaction product was collected and subjected to 10% Urea-PAGE followed by autoradiography. (**B**) Purification scheme of IREF-2 from uninfected HeLa cell NEs. For details regarding the column chromatography, see \'Materials and methods\'. (**C**) Profile of the fractions from Mono-Q column chromatography at the final purification step. Each Mono-Q fraction (fraction numbers 1--11) or input material for the Mono-Q column chromatography (i.e., unbound fraction of the Uno-S column chromatography) was individually added to this cell-free viral RNA synthesis reaction in the absence of any added primers (*upper panel*). Each Mono-Q fraction was subjected to 11.5% SDS-PAGE, and polypeptides were visualized by silver staining (*lower panel*). The closed arrowhead indicates 53 mer RNA products. The open arrowhead (50 mer) indicates the product possibly generated by internal priming of ApG. The arrows indicate two candidate peptides responsible for IREF-2 activity. The molecular weight (kDa) positions are denoted on the left side of the panel.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.003](10.7554/eLife.08939.003)

Structure of IREF-2-dependent RNA products {#s2-2}
------------------------------------------

To confirm the polarity of the IREF-2-dependent product, we carried out RNase T2 protection assays. ApG-primed RNA products using v53 and c53 as templates were also prepared as control materials ([Figure 2A](#fig2){ref-type="fig"}, lanes 1 and 4), in addition to the IREF-2-dependent RNA products (lane 7). Each radioactively labeled ApG-primed or unprimed 53 nt RNA product was hybridized with excess amounts of either the v53 or the c53 probe and then subjected to digestion with RNase T2, which preferentially digests ssRNA rather than dsRNA. Expectedly, the v53-directed ApG-primed RNA products were protected from digestion with RNase T2 by hybridization with the v53 probe (lane 2) but not the c53 probe (lane 3), whereas the c53-directed ApG-primed RNA products were protected by hybridization with the c53 probe (lane 6) but not with the v53 probe (lane 5), verifying the authenticity of this assay. The IREF-2-dependent RNA product was protected by hybridization with the c53 probe (lane 9) but not with the v53 probe (lane 8). These results clearly indicate that the IREF-2-dependent RNA product is of negative polarity, that is, vRNA.10.7554/eLife.08939.004Figure 2.Products of influenza virus replication factor-2 (IREF-2)-dependent unprimed RNA synthesis.(**A**) RNase T2 protection assay. Radioactively labeled vRNA products were synthesized in the cell-free viral RNA synthesis system with micrococcal nuclease-treated vRNP (mnRNP) and the v53 model template in the presence of ApG (lanes 1--3), the c53 model template in the presence of ApG (lanes 4--6), and c53 in the presence of the IREF-2 fraction and in the absence of ApG (lanes 7--9). Viral RNA products were hybridized with excess amounts of nonlabeled v53 (lanes 2, 5, and 8) or c53 (lanes 3, 6, and 9), which was followed by digestion with RNase T2. Hybridized and digested RNA samples were extracted, collected, and subjected to 10% Urea-PAGE followed by autoradiography visualization. The closed arrowhead indicates 53-nt-long RNAs. (**B**) Analysis of the 5\'-terminal structure of IREF-2-dependent unprimed vRNA products. \[α-^32^P\] GTP-labeled IREF-2-dependent unprimed vRNA products were prepared in the cell-free viral RNA synthesis system. The radioactively labeled 53-nt-long vRNA products were isolated from 10% Urea-PAGE, which was followed by excision and elution from the gel. A portion of the isolated 53-nt-long products was treated with alkaline phosphatase (lanes 2 and 4). Both nontreated and alkaline phosphatase-treated \[α-^32^P\] GTP-labeled unprimed vRNA products were digested with RNase T2 (lanes 1--4) or snake venom phosphodiesterase (lane 5). The digested materials were spotted onto a polyethylenimine (PEI)-cellulose thin layer and developed with 1 N acetic acid-4 M LiCl (4:1, v/v) (left panel; lanes 1 and 2) or 1.6 M LiCl (right panel; lanes 3--6) and visualized by autoradiography. For mobility standards, nonradiolabeled AMP, ADP, and ATP were also subjected to thin-layer chromatography and are indicated on the left side of each panel. For a marker of pppAp, \[γ-^32^P\] ATP-labeled v53 synthesized using T7 RNA polymerase was also subjected to RNase T2 digestion and then to thin-layer chromatography (lane 6). The expected nucleotide positions are indicated on the right side of each panel by closed arrowheads.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.004](10.7554/eLife.08939.004)

The other important point to be discussed regarding authentic vRNA replication is whether the vRNA product possesses a triphosphate moiety at its 5\'-terminus due to de novo initiation. Thus, we analyzed the structure of the 5\'-terminus of the IREF-2-dependent vRNA product ([Figure 2B](#fig2){ref-type="fig"}). The vRNA product synthesized in the presence of \[α-^32^P\] GTP as a radioactive substrate in the reaction was expected to have 5\'-xA\[^32^p\]Gp...-3\'. If the product is synthesized de novo, 'x' must be a triphosphate moiety (denoted as ppp). Upon digestion of the \[α-^32^P\] GTP-labeled IREF-2-dependent vRNA product with RNase T2, which cleaves on the 3\' side of a phosphodiester bond, pppA\[^32^p\] derived from the 5\'-terminus could be detected by thin-layer chromatography separation ([Figure 2B](#fig2){ref-type="fig"}, lanes 1 and 3). This product, putative pppA\[^32^p\], was not detected by treatment with alkaline phosphatase prior to RNase T2 digestion (lanes 2 and 4) or by digestion with snake venom phosphodiesterase (SV-PDE), which cleaves on the 5\' side of a phosphodiester bond (lane 5). These results clearly reveal that a triphosphate moiety is present at the 5\'-terminus of the IREF-2-dependent vRNA product, thereby indicating that the synthesis of this vRNA product is initiated de novo. Taken together, these results indicate that the IREF-2-dependent unprimed vRNA product is a bona fide unprimed vRNA replication product from the cRNA template.

Mass spectrometry analysis of IREF-2 proteins {#s2-3}
---------------------------------------------

Next, we attempted to reveal the identity of IREF-2α and β polypeptides. To this end, fraction numbers 6 (for IREF-2α, 32 kDa) and 9 (for IREF-2β, 31 kDa), shown in [Figure 1C](#fig1){ref-type="fig"}, were individually subjected to separation by SDS-PAGE, and polypeptides corresponding to IREF-2α (32 kDa) and β (31 kDa), were excised from the gel and then digested with trypsin. The trypsin-digested oligopeptides derived from IREF-2α and β were then analyzed using matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS). By comparing the molecular masses of the oligopeptides from each IREF-2 protein obtained by MALDI-TOF MS analysis (see [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}) with the database, we identified these IREF-2 proteins as follows: IREF-2α was shown to be identical to pp32 (phosphoprotein with a molecular mass of 32 kDa; accession number NP_006296) ([@bib28]) and also known as leucine-rich acidic nuclear protein, inhibitor of protein phosphatase 2A (I1pp2A), and putative HLA class II-associated protein I ([@bib29]). IREF-2β was shown to be identical to APRIL (acidic protein rich in leucines; accession number NP_006392) ([@bib30]), also named proliferation-related acidic leucine-rich protein or silver-stainable protein 29 ([@bib29]).

Both IREF-2α/pp32 and IREF-2β/APRIL exhibit high homology (71% sequence identity and 81% sequence similarity) and belong to the acidic nuclear phosphoprotein 32-kDa family (ANP32 family; pp32 and APRIL are also named ANP32A and ANP32B, respectively). These two proteins are encoded by separate genes and expressed mainly in the nuclei of variety kinds of tissues. Each IREF-2 protein is able to exist stably as a monomer and functions redundantly in multiple biological processes as an I1pp2A ([@bib25]), a ligand to HuR that stabilizes ARE-containing mRNA ([@bib5]), a component for INHAT activity ([@bib46]). The C terminus, comprising one-third of each protein, is extremely acidic, being composed of approximately 70% glutamic acid and aspartic acid residues, while the N-terminal region, comprising two-thirds of the protein, currently termed a leucine-rich-repeat, forms a horseshoe-shaped solenoid protein domain ([@bib16]; [@bib53]). By previous physical and regulatory mapping analyses, pp32 (ANP32A) was shown to be a host protein related to influenza virus infection ([@bib49]). In addition, a previous proteomic study identified pp32 and APRIL (ANP32B) as binding partners to the influenza vRdRP complex ([@bib3]). Recently, a genomewide RNAi screening study identified APRIL as one of nine 'top hit' genes affecting the viral RNA synthesis process in infected cells ([@bib55]). However, functional analyses for IREF-2/ANP32s have not been carried out, and thus their functional importance remains unclear.

Identification of pp32 and APRIL as IREF-2 {#s2-4}
------------------------------------------

Mono-Q chromatography could not separate IREF-2α/pp32 and IREF-2β/APRIL completely. Furthermore, several other polypeptides were also observed in these fractions ([Figure 1C](#fig1){ref-type="fig"}, fraction numbers 6--10). Therefore, we needed to confirm that pp32 and APRIL have authentic IREF-2 activity before any further molecular characterization. To this end, we prepared native and recombinant IREF-2 proteins and confirmed the quality of each protein preparation by silver staining and western blot analysis with anti-pp32 or anti-APRIL antibodies ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Both native and recombinant IREF-2 proteins supported cell-free unprimed RNA synthesis using mnRNP and the c53 model template in a dose-dependent manner ([Figure 3A](#fig3){ref-type="fig"}, lanes 2--4 and 5--7, or lanes 8--11 and 12--15, respectively). These results clearly indicate that pp32 and APRIL are authentic proteins responsible for IREF-2 activity, able to function independently of each other. We also tested the IREF-2 activity of an acidic protein, TAF-Iβ/SET ([@bib33]). TAF-Iβ/SET was reported to exhibit similar functions to pp32 as an inhibitor of PP2A phosphatase ([@bib26]) or INHAT ([@bib46]). TAF-Iβ/SET did not exhibit any IREF-2 activity at all (lanes 16--18), suggesting that its acidic property is insufficient for IREF-2 activity.10.7554/eLife.08939.005Figure 3.Characterization of influenza virus replication factor-2 (IREF-2) activities in the cell-free system.(**A**) Dose response of IREF-2. Native or recombinant IREF-2 proteins were added to the cell-free viral RNA (vRNA) synthesis reaction using micrococcal nuclease-treated vRNP (mnRNP) and the c53 model template in the absence of primer. Native pp32 (lanes 2--4), native APRIL (lanes 5--7), recombinant pp32 (lanes 8--11), and recombinant APRIL (lanes 12--15) were used as follows: 5 ng (lanes 2, 5, 8, and 12), 15 ng (lane 3, 6, 9, and 13), 50 ng (lanes 4, 7, 10, and 14) and 150 ng equivalent (lanes 11 and 15) of IREF-2 proteins. Recombinant TAF-Iβ/SET protein prepared using an *Escherichia. coli* expression system (33, 110, and 330 ng) was also tested (lanes 16--18). After incubation at 30°C for 2 hr, the RNA products were collected and analyzed by 10% Urea-PAGE followed by autoradiography. (**B**) Template preference of IREF-2-dependent viral RNA synthesis. Viral RNA replication reactions were performed in the cell-free viral RNA synthesis system using mnRNP and either v53 (lanes 1--5) or c53 (lanes 6--10) as viral model templates for vRNA and complementary RNA (cRNA), respectively. ApG at a final concentration of 0.2 mM (lanes 1 and 6) or 30, 100, and 300 ng of recombinant pp32 (lanes 3--5 and 8--10) was added to the reaction. (**C**) Effect of IREF-2 on cRNA synthesis from vRNP. Cell-free viral RNA synthesis using 2 ng PB1-equivalent of vRNP as the enzyme source and an endogenous genomic vRNA template were carried out in the presence (lane 1) or absence (lanes 2--8) of 0.2 mM ApG. Recombinant pp32 (lanes 3--5, 30, 100, and 300 ng, respectively) was added to the reactions. As a positive control, 1.5, 5, and 15 ng of recombinant IREF-1/MCM were also used (lanes 6--8). The RNA products were collected and analyzed by 4% Urea-PAGE followed by autoradiography. One-third (33%) of the total products derived from the ApG-primed cRNA synthesis were subjected to Urea-PAGE (lane 1). (**D**) Effect of IREF-2 on cap-snatching viral transcription. Cell-free viral RNA synthesis reactions were performed using mnRNP as the enzyme source and the exogenous model vRNA template (v53) in the presence of 0.2 mM ApG (lane 1) or globin mRNA as the 5'-capped RNA donor (lanes 2--5). Recombinant pp32 (lanes 3--5, 30, 100, and 300 ng, respectively) was added to the reaction.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.005](10.7554/eLife.08939.005)10.7554/eLife.08939.006Figure 3---figure supplement 1.Protein profiles of native and recombinant influenza virus replication factor-2 (IREF-2s).Native or recombinant IREF-2 proteins (50 ng) were subjected to 11.5% SDS-PAGE followed by silver staining (lanes 1--4) and western blot analysis with anti-pp32 antibody (lanes 5--8) or anti-APRIL antibody (lanes 9--12). The Mono-Q fraction 6 (shown in [Figure 1C](#fig1){ref-type="fig"}) was used as native pp32 (lanes 1, 5, and 9). Mono-Q fractions 9 and 10 (also shown in [Figure 1C](#fig1){ref-type="fig"}) were further purified with Mono-Q and used as native APRIL (lanes 2, 6, and 10). Recombinant pp32 (lanes 3, 7, and 11) and APRIL (lanes 4, 8, and 12) were prepared using the *Escherichia. coli* expression system, as described in \'Materials and methods\'.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.006](10.7554/eLife.08939.006)

We therefore next examined the template preference of IREF-2. Either v53 or c53 was used as the model RNA template for the cell-free reactions ([Figure 3B](#fig3){ref-type="fig"}). Notably, the unprimed RNA product was observed from the cRNA template in an IREF-2-dependent manner ([Figure 3B](#fig3){ref-type="fig"}, lanes 8--10), but a significant level of cRNA synthesis was not detected when the vRNA template was used (lanes 3--5). These results suggest that IREF-2 preferentially regulates vRNA synthesis from the cRNA template, that is, the second step of the replication mechanism. Furthermore, the effect of IREF-2 on cRNA synthesis from the vRNP complex was also examined ([Figure 3C](#fig3){ref-type="fig"}). Cell-free viral RNA synthesis using vRNP complexes as the enzyme and endogenous vRNA template source, that is, the vRdRP and genomic vRNA of each segment, was performed in the absence of a primer. As previously observed, replicative cRNA synthesis from the genomic vRNA templates was stimulated by recombinant IREF-1/MCM ([Figure 3C](#fig3){ref-type="fig"}, lanes 6--8), which is known to stimulate promoter clearance during replication ([@bib20]). In contrast, no significant change induced by pp32 was observed (lanes 3--5). This finding indicates that IREF-2 is not involved in cRNA synthesis from endogenous vRNA and that the function of IREF-2 is distinct from that of IREF-1/MCM. This observation also confirms the template polarity preference of IREF-2 ([Figure 3B](#fig3){ref-type="fig"}).

Next, to address whether IREF-2 affects viral transcription, cap-snatching viral transcription was performed in the cell-free system using 5'-capped mRNA of β-globin (GmRNA) as a 5'-cap donor for viral transcription ([Figure 3D](#fig3){ref-type="fig"}). By adding GmRNA instead of ApG, the transcriptional product could be detected at a 10--12 nt longer size than that of the vRNA template (compare lanes 1 and 2), consistent with the findings of a previous report ([@bib41]). After addition of pp32 to this cell-free transcription reaction, no obvious change was observed (lanes 3--5), suggesting that IREF-2 has neither a positive nor a negative effect on viral mRNA transcription.

Interaction between IREF-2 and viral RNA polymerases {#s2-5}
----------------------------------------------------

To determine a regulatory target(s) of IREF-2, we performed interaction assays using IREF-2 and viral factors related to the viral RNA synthesis process. To date, no report has been published showing that pp32 and APRIL bind directly to RNA. In fact, the interaction between IREF-2 proteins and the model RNA template was not observed ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Therefore, we performed GST pull-down assays using lysates prepared from mammalian cells (HEK293T) expressing GST-tagged IREF-2 (GST-IREF-2). Forty-eight hours after transfection with GST-derivative expression plasmids, the cells were infected with influenza virus at a multiplicity of infection (MOI) of 3 for 6 hr, and the viral factors bound to the GST-protein were then analyzed. Each subunit of the vRdRP complex (PB1, PB2, and PA) was co-precipitated with both GST-pp32 and GST-APRIL, but NP was not ([Figure 4A](#fig4){ref-type="fig"}, lanes 2 and 3). Instead, only NP was co-precipitated with GST-RAF2p48, which functions as a chaperone for NP ([@bib31]) (lane 4). To further confirm this, lysates prepared from cells exogenously expressing polymerases ([Figure 4B](#fig4){ref-type="fig"}, lanes 1--4) or NP (lanes 5--8) and GST-derivative proteins were also examined. Exogenously expressed trimeric complexes of the viral polymerases were co-precipitated with both GST-pp32 and GST-APRIL (lanes 2 and 3), but NP was not detected at all (lanes 6 and 7). GST-RAF2p48 interacted with NP, but not with any polymerase subunits (lanes 4 and 8). Thus, we concluded that the binding target of IREF-2 is the trimeric complex of vRdRP, not NP. Moreover, the fact that the interaction between IREF-2 and NP could not be observed in the infected cells suggested that IREF-2 might interact with a free form of vRdRP, but not with vRdRP, in RNP complexes in infected cells. To confirm this, the amount of viral RNA in the complex of IREF-2 and vRdRP was quantitatively determined. Complexes of GST-pp32 with vRdRP were prepared from infected cells by GST pull-down, as shown in [Figure 4A](#fig4){ref-type="fig"} (lane 2). The RNA pulled down with the complexes was then extracted, and the amount of viral RNA (here, segment 5) was determined by reverse transcription-mediated quantitative PCR (RT-qPCR). We found that 1 pmol of vRdRP complexed with GST-pp32 contains \<0.5 fmol of segment 5 (vRNA, cRNA, and viral mRNA) only, suggesting that IREF-2 tends to interact with a free form of vRdRP in infected cells.10.7554/eLife.08939.007Figure 4.Interaction of influenza virus replication factor-2 (IREF-2) proteins with free forms of viral polymerase trimeric complexes.(**A**) Interaction between IREF-2 and viral proteins in infected cells. HEK293T cells were transfected with 10 μg of plasmids expressing GSTnls (lane 1), GST-pp32 (lane 2), GST-APRIL (lane 3), and GST-RAF2p48 (lane 4). At 48 hr post transfection, influenza virus was infected at an multiplicity of infection (MOI) of 3. At 6 hr post infection, the transfected and infected cells were collected, lysed, and subjected to GST pull-down assays, as described in \'Materials and methods\'. The pulled-down materials and 3% equivalent of the input samples were subjected to SDS-PAGE followed by western blot analysis with anti-PB1, -PB2, -PA, -NP, and -GST (only the pull-down sample) antibodies. (**B**) Interaction between IREF-2 and viral proteins in the transfected cells. HEK293T cells were transfected with 5 μg of plasmids expressing GSTnls (lanes 1 and 5), GST-pp32 (lanes 2 and 6), GST-APRIL (lanes 3 and 7), and GST-RAF2p48 (lanes 4 and 8) and also co-transfected with the plasmids for the viral polymerase subunits (5 μg of pCAGGS-PB1, 12.5 μg of pCAGGS-PB2, and 2.5 μg of pCAGGS-PA \[lanes 1--4\] or 10 μg of pCAGGS-NP for NP expression \[lanes 5--8\]). Forty-eight hours post transfection, the cotransfected cells were collected, lysed, and subjected to GST pull-down assays. The input samples (3%) and pulled-down materials were subjected to SDS-PAGE followed by western blot analysis. (**C**) Interaction between IREF-2 and trimeric or binary complexes of vRdRP. HEK293T cells were cotransfected with 5 μg of plasmids expressing GSTnls (lanes 1, 4, and 7), GST-pp32 (lanes 2, 5, and 6), GST-APRIL (lanes 3, 6, and 9), 5 μg of pCAGGS-PB1cFlag (lanes 1--9), 12.5 μg of pCAGGS-PB2 (lanes 1--6), and 2.5 μg of pCAGGS-PA (lanes 1--3 and 7--9). Forty-eight hours post transfection, the lysates from the cotransfected cells were subjected to GST pull-down assays or immunoprecipitation assays with anti-Flag antibody. The precipitated materials were subjected to SDS-PAGE followed by western blot analysis.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.007](10.7554/eLife.08939.007)10.7554/eLife.08939.008Figure 4---figure supplement 1.Electrophoresis mobility shift assay for influenza virus replication factor-2 (IREF-2) and viral RNA.Radioactively labeled 53-nt-long model vRNA and complementary RNA(cRNA) probes (v53 and c53; 246.9 cpm/fmol) were synthesized by T7 RNA polymerase using \[α-^32^P\] GTP and isolated by gel excision. Each 500 pM (final concentration) of the labeled viral RNA probes, v53 (lanes 1--7) and c53 (lanes 8--14) was incubated with 10 nM or 50 nM of recombinant NP prepared using the *Escherichia. coli* expression system (lanes 2, 3, 9, and 10), recombinant pp32 (lanes 4, 5, 11, and 12), and recombinant APRIL (lanes 6, 7, 13, and 14) in 50 mM HEPES-NaOH (pH 7.9), 50 mM KCl, 0.5 U/μl of RNase inhibitor, and 15% (v/v) glycerol at 30°C for 30 min. After incubation, each binding mixture was loaded onto 0.6% agarose gel (buffered with TBE) and separated by electrophoresis (50 V for 3 hr). The gel was dried and visualized by autoradiography.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.008](10.7554/eLife.08939.008)10.7554/eLife.08939.009Figure 4---figure supplement 2.Interaction between viral RNA-dependent RNA polymerase (vRdRP) complexes and endogenous influenza virus replication factor-2 (IREF-2).HEK293T cells were transfected with plasmids expressing PB1 (lane 2) or PB1cFlag (lanes 3--5), PB2 (lanes 2--4), and PA (lanes 2, 3, and 5), as indicated. At 48 hr post transfection, the cells were harvested, lysed, and subjected to immunoprecipitation assays using anti-Flag antibody, as described in \'Materials and methods\'. Input and precipitated materials were analyzed by SDS-PAGE, followed by western blot analysis using the antibodies indicated on the right side of each panel.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.009](10.7554/eLife.08939.009)

We also tried to determine which subunit of vRdRP is the binding target of IREF-2. Cells expressing GST-tagged derivative proteins and vRdRP trimeric complexes or binary subcomplexes were prepared and subjected to GST pull-down assays ([Figure 4C](#fig4){ref-type="fig"}). Here, a Flag epitope tag was attached to the PB1 subunit, and formation of vRdRP subcomplexes, such as a trimeric complex (lanes 1--3) and a binary complex of PB1-PB2 (lanes 4--6) and of PB1-PA (lanes 7--9), was confirmed by immunoprecipitation with anti-Flag antibodies ('Flag IP' panels). Neither of the binary subcomplexes was pulled down with GST-IREF-2 ('GST pull-down' panels, lanes 5, 6, 8, and 9), whereas the interaction with IREF-2 could be observed for the vRdRP trimeric complex (lanes 2 and 3). A similar characteristic interaction property could be observed for each endogenous IREF-2 protein ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Consistent with this observation, each IREF-2 protein was previously reported to be associated with the vRdRP trimeric complex, but not with the binary complex of PB1-PA ([@bib3]). And interestingly, the PB1-PB2 subcomplex was also found not to be associated with IREF-2, as shown here. This result strongly suggests that both the PA and the PB2 subunits in the trimeric complex of vRdRP are requisite for stable interaction with IREF-2.

Effect of IREF-2 on viral RNA synthesis in infected cells {#s2-6}
---------------------------------------------------------

Using a cell-free viral RNA synthesis system, we demonstrated that IREF-2 enables vRdRP to replicate vRNA from a cRNA template preferentially. Next, to show the function of IREF-2 in vivo, the effect of IREF-2 KD on viral RNA synthesis in infected cells was examined. By transfection with short RNAi duplexes targeting pp32 and APRIL, the expression levels of both proteins were strongly blocked ([Figure 5A](#fig5){ref-type="fig"}). Both the control KD and the IREF-2 KD cells were infected with influenza virus, and the intracellular viral RNA level was measured. Upon KD of pp32 or APRIL, the levels of vRNA, cRNA, and viral mRNA decreased to about 50% to --80% of the control level in each infection period ([Figure 5B](#fig5){ref-type="fig"}). By silencing both pp32 and APRIL ('double-KD' cells; see [Figure 5A](#fig5){ref-type="fig"}, lane 6), each viral RNA level was additively decreased to about 25% to -- 50% of the control level ([Figure 5B](#fig5){ref-type="fig"}). These results suggest that IREF-2, pp32, and APRIL redundantly play a positive role in viral RNA synthesis in infected cells. Although IREF-2 was shown to preferentially regulate vRNA synthesis from a cRNA template in a cell-free system, the decrease patterns of the vRNA, cRNA, and viral mRNA syntheses were comparable in the IREF-2 KD cells.10.7554/eLife.08939.010Figure 5.Effect of influenza virus replication factor-2 (IREF-2) knockdown in infected cells.(**A**) Endogenous IREF-2 protein levels in knockdown (KD) HeLa cells. The whole-cell lysates of control KD cells (lane 3), pp32 KD cells (lane 4), APRIL KD cells (lane 5), and both pp32 and APRIL KD cells (termed double-KD cells; lane 6) were subjected to SDS-PAGE followed by western blot analysis with antibodies, as indicated on the right side of the panel. To measure the KD levels, 10% and 30% of the lysates of the control KD cells were also subjected to SDS-PAGE followed by western blot analysis with antibodies, respectively (lanes 1 and 2). (**B**) Viral RNA levels in infected KD HeLa cells. Total RNA was extracted from mock-infected or infected KD cells at an multiplicity of infection (MOI) of 1 at 3, 6, and 9 hr post infection. vRNA, complementary RNA(cRNA), and viral mRNA derived from segment 5 were quantitatively determined by RT-mediated qPCR (RT-qPCR), as described in \'Materials and methods\'. (**C**) Primary transcription level in infected KD HeLa cells. Total RNA was extracted from mock-infected or infected KD cells at an MOI of 10 for 3 hr in the presence or absence of cycloheximide (CHX). Viral mRNA derived from segment 5 was quantitatively determined by RT-qPCR. (**D**) Effect of IREF-2 on progeny virus production. Control KD and IREF-2 double-KD A549 cells were infected with FluV (WSN/33 strain) at an MOI of 0.001. The number of infectious progeny viruses produced from control KD and IREF-2 double-KD A549 cells at each time point were plotted (*upper panel*), and the ratios of progeny viruses produced from IREF-2 double-KD A549 cells compared with those from control KD cells were also represented as a percentage of the control (*lower panel*). Each quantitative result is presented as the average with the standard deviation from at least three independent experiments. Significance was determined using Student's *t* test. n.s.: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.010](10.7554/eLife.08939.010)10.7554/eLife.08939.011Figure 5---figure supplement 1.Effect of influenza virus replication factor-2 (IREF-2) on viral reporter RNA syntheses from a reconstituted model replicon.HEK293T of control and IREF-2 knockdown (KD) cells (approximately, 3 × 10^5^ cells in a 22-mm-diameter dish) were transfected with expression plasmids pCAGGS-PB1, -PB2, -PA, and -NP (15 ng each). In addition, 1.5 ng of either phPolI-vNS-Luc (for expression of vNS-Luc; *left panel*) or phPolI-cNS-Luc (for expression of cNS-Luc; *right panel*) was co-transfected as a viral genomic source. At 24 hr post co-transfection, viral reporter levels in both the control KD and the IREF-2 KD cells were quantitatively determined by RT-qPCR as described previously ([@bib19]) and in \'Materials and methods\'. Quantification and standard deviations of the viral reporter RNA levels from IREF-2 KD cells expressed as a percentage of the value from the control KD cells. Each experiment was repeated three times.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.011](10.7554/eLife.08939.011)

We tried to address whether the effect of IREF-2 on vRNA and cRNA syntheses could be distinguished by using a mini-genome replicon system with either the vRNA reporter (vNS-Luc) or the cRNA reporter (cNS-Luc) as the source of the viral genome ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In both templates, the levels of three kinds of viral RNAs were shown to be significantly decreased by IREF-2 KD as observed in the infected IREF-2 KD cells ([Figure 5B](#fig5){ref-type="fig"}). On the basis of the assumption that IREF-2 preferentially stimulates vRNA synthesis rather than cRNA synthesis, the vRNA level is expected to be more reduced by IREF-2 KD than the cRNA level in these experiments. In the case of vNS-Luc as a viral genomic source, the vRNA level appeared to be slightly more decreased by IREF-2 KD (12% of the control) when compared with the decrease in the cRNA level (23% of the control). Meanwhile, all viral reporter RNA levels were shown to be decreased almost comparably (46%--- 48% reductions) when cNS-luc was used. From these results, the difference in the reduction level of vRNA and cRNA was insufficient to distinguish the effects of IREF-2 KD on vRNA and cRNA syntheses in these reporter experiments. This could be interpreted as follows: vRNA serves as a template for cRNA synthesis and mRNA transcription, and cRNA serves as a template for vRNA synthesis. Therefore, a defect in a certain specific step of viral RNA synthesis would influence the other steps and would result in declines in the accumulation levels of all viral RNA species, as observed in a previous study ([@bib27]).

Next, we tried to address whether IREF-2 plays a role in transcription. To examine the effect of IREF-2 KD on primary transcription, we used a translation inhibitor, cycloheximide. In infected cells, cycloheximide prevents the synthesis of viral proteins required for the viral RNA replication process, resulting in the blockage of cRNA and vRNA syntheses. Therefore, only viral mRNA synthesis from incoming vRNP is detectable in the presence of cycloheximide. Control KD and pp32 and APRIL double-KD cells (identical to lanes 3 and 6 in [Figure 5A](#fig5){ref-type="fig"}) were infected at high multiplicity (MOI of 10) for 3 hr in the presence or absence of cycloheximide. In the presence of cycloheximide, the accumulation level of the primary transcription appeared to be almost the same for the control KD and IREF-2 double-KD cells, while in the absence of cycloheximide, a significant reduction was observed in the IREF-2 double-KD cells ([Figure 5C](#fig5){ref-type="fig"}). These results demonstrate that IREF-2 had no effect on the primary transcription, consistent with the result presented in [Figure 3D](#fig3){ref-type="fig"} showing that IREF-2 had no effect on the cap-snatching transcription in the cell-free reaction system. Thus, it is quite possible that IREF-2 stimulates viral RNA replication in vivo. Nevertheless the function of IREF-2 in cRNA synthesis and vRNA synthesis was not distinguishable in these experiments.

Finally, the effect of IREF-2 KD on virus growth was examined by using human alveolar basal epithelial cells (A549 cell line). Upon silencing both IREF-2 proteins (IREF-2 double-KD), significant decrease in progeny virus production (approximately, 90% of reduction at each time point) could be observed ([Figure 5D](#fig5){ref-type="fig"}). This seems to be attributable to the deficiency in the viral RNA replication process caused by IREF-2 KD.

Discussion {#s3}
==========

In this study, we have identified IREF-2 consisting of pp32 and APRIL as host factors, which upregulate the second step of influenza viral RNA replication, that is, vRNA synthesis from a cRNA template. These host factors are well known as members of the ANP32 family and exhibit high homology with each other. Both are evolutionarily conserved in many organisms, including birds and swine, and are ubiquitously expressed in a variety of tissues, including lung tissue. Recently, an small-interfering RNA (siRNA) screening study suggested that APRIL is a positive regulator of viral RNA biogenesis ([@bib55]). In that report, the interaction between host proteins and viral factors singly expressed in mammalian cells was also examined, but interaction between APRIL with vRdRP subunit was not observed, and the authors speculated that the effect of APRIL on viral RNA synthesis might be indirect. However, we have shown that IREF-2 can interact efficiently with the trimeric complex of PB1, PB2, and PA, but not with any subcomplexes ([Figure 4C](#fig4){ref-type="fig"}). Therefore, APRIL seems not to be co-precipitated with any singly expressed vRdRP subunit ([@bib55]). It is noteworthy that interaction between IREF-2 and the vRdRP trimeric complexes was observed in infected cells and cells cotransfected with all three subunit expression vectors, while interaction with the RNP complexes could not be observed in the infected cells ([Figure 4A](#fig4){ref-type="fig"}). On the basis of these observations, the interaction between IREF-2 and vRdRP appears to be temporary during the process of cRNA template binding and vRNA synthesis, and once vRdRP starts vRNA synthesis, the associating IREF-2 protein may be released from vRdRP. The exact timing of the release of IREF-2 from the RNP complexes during replication, for example, at the initiation step of vRNA synthesis, during the transition step from initiation to elongation, or during elongation, remains to be solved. Cell-free analyses clearly demonstrated that IREF-2 is preferentially involved in vRNA synthesis from the cRNA template rather than in cRNA synthesis from the vRNA template ([Figures 3B,C](#fig3){ref-type="fig"}). The accumulation level of viral RNA in infected IREF-2 KD cells was significantly decreased, but not completely abolished ([Figure 5B](#fig5){ref-type="fig"}). This incomplete abolishment could be interpreted as due to the involvement of another unidentified host factor(s) in the viral RNA replication process. Recent studies have demonstrated that viral NS2 protein and virus-induced small leader RNA play important roles in the RNA replication process ([@bib37]; [@bib38]; [@bib45]). Taken together, these findings suggest that the negative effect of IREF-2 KD on viral RNA replication might be compensated by other host and/or viral factor(s) and/or other regulation mechanism(s) and that viral replication at some limited level could still be observed in IREF-2 KD cells.

Apparently, the function of IREF-2 is distinct from that of IREF-1/MCM ([Figure 3C](#fig3){ref-type="fig"}), which plays a role in promoter clearance during viral RNA synthesis, but how and in which step IREF-2 is involved is unclear. Previously, Deng et al demonstrated that the initiation steps of vRNA synthesis and cRNA synthesis take place in different ways: vRNA synthesis is initiated in an 'internal initiation and realignment' manner, whereas cRNA synthesis is initiated at the 3'-terminus of the vRNA template ([@bib8]). The reported initiation mechanism of vRNA synthesis in this model describes that dinucleotide pppApG is internally synthesized de novo so as to be complementary to U^4^C^5^ (in which the numbers indicate the nucleotide positions of the cRNA from the 3'-terminus and are denoted as 'c3'U4C5' in the discussion below). The 3'-terminal sequence of cRNA is composed of 3\'-U^1^C^2^A^3^U^4^C^5^... -5\'. Therefore, this internally synthesized pppApG would be realigned to the 3'-terminal nucleotide positions 1 and 2 (denoted as 'c3'U1C2') of the template cRNA, followed by subsequent extension resulting in the full-length vRNA product. On the basis of this model ([@bib8]), the differential effect of IREF-2 on vRNA and cRNA synthesis ([Figure 3B](#fig3){ref-type="fig"}) leads to the hypothetical speculation that IREF-2 functions at an initiation process specific to vRNA synthesis using cRNA as the template. In another previous report by Zhang et al, unprimed vRNA synthesis appears to be initiated de novo at the c3'U4C5 position of the cRNA template but 'realignment' does not take place. And vRdRP extends a nascent RNA chain from the internal position, resulting in a short vRNA product lacking the first three nucleotides at the 5\'-terminal sequence of the authentic vRNA product ([@bib58]). In their cell-free vRNA synthesis system, such abnormal 3 nt-shorter vRNA was a major product, whereas full-sized vRNA was synthesized only to a limited extent at high concentrations of the UTP substrate. In our study, however, IREF-2-dependent vRNA products were shown to be exclusively full length. Taking these results together, we postulated that IREF-2 regulates the initiation step of vRNA synthesis as follows: (1) by preventing improper extension prior to pppApG realignment, (2) by facilitating the conformational change of vRdRP and/or the cRNA template to promote the realignment, and/or (3) by stabilizing the initiation-intermediate complex when pppApG is already realigned onto c3\'U1C2 and ready for proper elongation. To address these possibilities, further functional studies are needed.

In the two previous reports by Deng et al. and Zhang et al., cell-free vRNA synthesis could be reproduced without any exogenously added primer and host proteins, while in our cell-free system, no vRNA synthesis occurred without any added primer and host proteins, as was observed previously ([@bib11]; [@bib47]; [@bib47]). They used recombinant vRdRP purified from plasmid-transfected mammalian cells ([@bib8]) or baculovirus-infected insect cells ([@bib58]; [@bib59]), while we used mainly mnRNP prepared by treatment of virion-derived vRNP complexes with MNase as the enzyme source. Therefore, the intrinsic nature of vRdRPs seems to differ one from the other, and recombinant vRdRP is possibly competent to initiate spontaneously de novo vRNA synthesis to some extent. Another difference among these enzyme sources is the presence of NP in the mnRNP preparation. At present, several lines of evidence suggest that NP plays a positive role(s) in regulation of vRdRP for replication and nascent chain elongation, but in the present study, unprimed vRNA synthesis employing mnRNP was not observed even in the presence of NP (lanes 2 and 10 in [Figure 1A](#fig1){ref-type="fig"}, and elsewhere). On the other hand, in previously reported preparations of recombinant vRdRP, some host proteins were possibly contaminated ([@bib7]; [@bib59]), and an unexpected contribution(s) of such host protein contamination to their cell-free reactions could not be completely excluded. The other point for consideration is that the amount of vRdRP used in the cell-free reactions was different. In their cell-free reaction systems, a relatively large amount (100 nM) of vRdRP was used for the reaction ([@bib58]), while we used a much smaller amount of the enzyme source (approximately 2--3 nM of vRdRP equivalent mnRNP) in the reaction. Hence, spontaneous vRNA synthesis in the absence of any primer and host factor might have taken place to some extent in their cell-free system. Taking such differences in the quality and quantity of the enzyme sources into account, it is possible that vRdRP intrinsically possesses de novo initiation activity and that IREF-2 may increase the turnover efficiency so that the apparent concentration of vRdRP seems to be increased. At this point, one of the primary interests to be addressed is whether IREF-2 exhibits similar stimulation activity as observed here in the cell-free system using recombinant vRdRP. In addition, the relationship between IREF-2 and NP has also not been addressed because mnRNP was used mainly as an enzyme source throughout this study. Therefore, NP-free vRdRP (i.e., recombinant vRdRP) seems to be a suitable enzyme source to address whether NP is necessary for the regulatory mechanism by IREF-2. These differences in the quality and quantity of vRdRP must be taken into account for further study. Lastly, we have shown by cell-free studies that IREF-2 is involved in regulation of unprimed vRNA synthesis but not of cRNA synthesis ([Figures 3B,C](#fig3){ref-type="fig"}). However, it is possible that our cell-free system might not be completely appropriate or sufficient for cRNA synthesis from a vRNA template, and thus we do not exclude the possibility that IREF-2 also functions in unprimed cRNA synthesis. If virion-derived vRdRP, including mnRNP, could be set up to be adapted to the transcriptional mode rather than to the (cRNA) replicative mode, some process might be required for neutralizing the transcriptional mode of vRdRP or switching the mode from 'transcriptase' to 'replicase'. Given this possibility, not only IREF-2 but also an additional factor(s) might be required for efficient unprimed cRNA synthesis in our cell-free system. To confirm this possibility, we are currently preparing recombinant vRdRP complexes possibly with the intrinsic property of influenza vRdRP as 'replicase' in infected cells for use in examining the effect of IREF-2.

In conclusion, we have demonstrated that the novel host-derived factors pp32 and APRIL regulate vRNA synthesis at least from the cRNA template. However, a number of questions about the function of IREF-2 remain unanswered. It would be important and beneficial to use recombinant vRdRP with high-purity and an authentic nature as an enzyme source in further detailed studies. In addition, the crystal structure of influenza vRdRP was recently resolved ([@bib39]; [@bib44]), and therefore, the structure-based mechanism of IREF-2 will likely be elucidated in future studies.

Materials and methods {#s4}
=====================

Cell culture, virus, and antibodies {#s4-1}
-----------------------------------

Cells from the human cervical carcinoma HeLa S3 cell line were cultured in a spinner flask with Eagle's minimal essential medium for suspension cultures (S-MEM; Sigma, St. Louis, MO) containing 10% calf serum. The medium was added to the suspension cell culture to maintain a density of 2--6 × 10^5^ cells/ml. When the volume of the suspension cell culture reached 10 liters, the cells were collected by centrifugation and used for preparation of the NEs. HEK293T and A549 cells were grown at 37°C in Dulbecco's modified Eagle's medium (DMEM; Nissui, Japan) containing 10% fetal calf serum, and monolayer HeLa cells were cultured in Eagle's minimal essential medium (MEM; Sigma) containing 10% fetal calf serum, termed as MEM(+).

Influenza virus A/PR/8/34 (H1N1) was grown in the allantoic sacs of 10-day-old embryonated eggs. The viruses were purified from infected allantoic fluid as described previously ([@bib22]) and used for vRNP preparation.

Anti-pp32 (goat polyclonal; Santa Cruz Biotechnology, Dallas, TX), anti-APRIL (goat polyclonal; Abcam limited, UK), and anti-GST (mouse polyclonal; Nacalai Tesque, Japan) antibodies were commercially purchased. For detection of viral proteins, rabbit polyclonal anti-PB1, -PB2, -PA, and -NP antisera were prepared as previously described ([@bib31]; [@bib32]) and used for western blot analysis.

Cell-free viral RNA synthesis {#s4-2}
-----------------------------

vRNP complexes were prepared from the purified influenza A/PR/8/34 virus as described previously ([@bib51]). mnRNP was prepared by incubation of vRNP complexes at 30°C for 2 hr with one unit of micrococcal nuclease (Roche Molecular Biochemicals, Schweiz)/μl in the presence of 1 mM CaCl~2~. The nuclease reaction was terminated by addition of EGTA to a final concentration of 3 mM. The 53 nt-long viral model RNAs (v53; 5\'-AGUAGAAACAAGGGUGUUUUUUCAUAUCAUUUAAACUUCACCCUGCUUUUGCU-3\' and c53; 5\'-AGCAAAAGCAGGGUGAAGUUUAAAUGAUAUGAAAAAACACCCUUGUUUCUACU-3\') were synthesized by transcription with RiboMAX Large Scale RNA Production System-T7 (Promega, Madison, WI) using a synthetic DNA template as previously described ([@bib51]). Cell-free viral RNA synthesis was carried out at 30°C in a final volume of 20 μl or 25 μl in the presence of 50 mM HEPES-NaOH (pH 7.9), 3 mM MgCl~2~, 50 mM KCl, 1 mM DTT, 500 μM each of ATP, UTP, and CTP and 25 μM GTP, 5 μCi of \[α-^32^P\] GTP (3000 Ci/mmol), 8 U of RNase inhibitor from human placenta (Toyobo, Japan), 10 ng of a 53-nt-long model viral RNA template of negative or positive polarity (v53 and c53, respectively) and approximately 40 ng NP-equivalent, alternatively 5 ng PB1-equivalent of mnRNP as an enzyme source. After incubation, the reactions were terminated by phenol/chloroform extraction followed by precipitation of the RNA products with ethanol. The precipitated materials were subjected to polyacrylamide gel electrophoresis in the presence of urea (Urea-PAGE) and visualized by autoradiography.

Purification of native IREF-2s from NEs {#s4-3}
---------------------------------------

All procedures for preparation and fractionation of the NEs were carried out at 4°C or on ice. The details for purification is described at Bio-protocol ([@bib52]). Briefly, uninfected HeLa cell NE was prepared as described previously ([@bib10]). For fractionation of the NE, a buffer (buffer H) containing 50 mM HEPES-NaOH (pH 7.9), 20% (v/v) glycerol, and 1 mM DTT in the presence of the appropriate concentrations of KCl was used for ion-exchange chromatography for purification of IREF-2. The purification scheme started with NE containing 15 mg protein. NE was loaded onto a phosphocellulose column (10-ml bed volume; Whatman P11) equilibrated with buffer H containing 50 mM KCl and successively eluted stepwise with buffer H containing 0.2 M, 0.5 M, and 1.0 M KCl. An unbound fraction (P0.05) and fractions eluted with 0.2 M (P0.2), 0.5 M (P0.5), and 1.0 M (P1.0) of KCl were examined by the cell-free viral RNA synthesis system. The remaining P0.05 fraction was loaded onto an anion exchanger Uno-Q column (Bio-Rad, Hercules, CA) equilibrated with buffer H containing 50 mM KCl and eluted stepwise with increasing concentrations of KCl. The IREF-2 activity fraction eluted with buffer H containing 0.6 M KCl was diluted with buffer H and again loaded onto the Uno-Q column equilibrated with buffer H containing 0.25 M KCl. The IREF-2 activity was eluted with a linear gradient of 0.25 M to --0.8 M KCl in buffer H. The concentrated IREF-2 fraction was diluted two-fold with an equal volume of a buffer containing 50 mM HEPES-NaOH (pH 7.9), 1 mM DTT, and 2.0 M (NH~4~)~2~SO~4~ and loaded onto a hydrophobic SOURCE-PHE column (GE Healthcare, Piscataway, NJ) equilibrated with a buffer containing 50 mM HEPES-NaOH (pH 7.9), 10% (v/v) glycerol, 1 mM DTT, and 1.0 M (NH~4~)~2~SO~4~. The IREF-2 activity was unbound to the hydrophobic column and dialyzed with buffer H containing 30 mM KCl. The dialyzed IREF-2 fraction was loaded onto a cation exchanger (Uno-S, Bio-Rad), and the IREF-2 activity was recovered in the fraction unbound to the column. Finally, the IREF-2 fraction was load onto an anion axcahnger (Mono-Q column; GE Healthcare), and the materials captured by the column were eluted with a linear gradient of 0.35--0.7 M KCl in buffer H.

RNase T2 protection assay and thin-layer chromatography {#s4-4}
-------------------------------------------------------

For the RNase T2 protection assay, one-third of \[α-^32^P\] GTP-radiolabeled total RNA products synthesized by the cell-free viral RNA synthesis reactions were hybridized with either a nonradiolabeled v53 or a c53 probe by incubation at 85°C for 10 min, followed by incubation at 60°C for 10 min in a hybridization buffer (40 mM PIPES-NaOH \[pH 6.4\], 1 mM EDTA, 0.4 M NaCl, and 80% formamide) and gradual cooling down to room temperature ([@bib51]). Each hybridized RNA product was subjected to RNase T2 digestion (five units in 20 mM NaOAc \[pH 5.2\]) at 25°C for 1 hr. Digestion was terminated by phenol/chloroform extraction, and the digested materials were collected by ethanol precipitation. The precipitated materials were subjected to 10% Urea-PAGE and visualized by autoradiography. At the same time, the remaining one-third of the total RNA products was also subjected to Urea-PAGE as an undigested sample.

For analysis of the 5\''-terminus of the unprimed IREF-2-dependent RNA products, RNase digestion and thin-layer chromatography were performed as described previously ([@bib20]). After purification by 10% Urea-PAGE and elution from the gel piece, the purified \[α-^32^P\] GTP-radiolabeled RNA products were digested with 15 units of RNase T2 in 50 mM NaOAc (pH 5.0), 100 mM NaCl, and 2 mM EDTA, or 0.5 units of SV-PDE in 50 mM Tris-HCl (pH 9.0), 100 mM NaCl, and 14 mM MgCl~2~ at 37°C for 1 hr. The digested products were spotted onto a PEI-cellulose thin layer (Merck, Germany) and developed with 1.6 M LiCl or 1 N acetic acid-4 M LiCl (4:1, v/v) and visualized by autoradiography. In the case of alkaline phosphatase treatment, \[α-^32^P\] GTP-labeled product was incubated with 0.5 units of bacterial alkaline phosphatase in a buffer recommended by the manufacturer (Toyobo) at 37°C for 1 hr before nuclease digestion. For mobility standards, nonradioactive adenosine monophosphate (AMP), adenosine diphosphate (ADP), and adenosine triphosphate (ATP) were subjected to thin-layer chromatography. For a marker of adenosine 5\'-triphosphate and 3\'-monophosphate (pppAp), \[γ-^32^P\] ATP-labeled v53 synthesized with T7 RNA polymerase was also subjected to gel purification, nuclease digestion, and thin-layer chromatography as described above.

GST pull-down assay from mammalian cells {#s4-5}
----------------------------------------

Transfected and infected HEK293T cells were harvested with a rubber policeman and washed with PBS(-). The collected cells were suspended in an ice-cold lysis-binding buffer (50 mM Hepes-NaOH \[pH 7.9\], 100 mM NaCl, 50 mM KCl, 0.25% NP-40, and 1 mM DTT) and lysed by brief sonication. After centrifugation, the crude lysates were incubated with Glutathione-Sepharose 4B resin (GE Healthcare) at 4°C for 1 hr. After incubation, the resins were collected by brief centrifugation and washed three times with the lysis-binding buffer. The resin-bound materials were eluted by boiling in the SDS-PAGE loading buffer and subjected to SDS-PAGE, which was followed by detection with the standard western blot analysis procedure.

RNA isolation, reverse transcription, and quantification by RT- PCR {#s4-6}
-------------------------------------------------------------------

Total RNA from infected HeLa cells or transfected 293T cells was extracted using Sepasol-RNA I Super G (Nacalai Tesque) according to the manufacturer's instructions. The extracted RNA was treated with DNase I and subjected to RT reaction as follows. For synthesis of cDNA derived from segment 5 viral RNAs, each specific primer was used in the RT reaction, as follows: 5\'-GACGATGCAACGGCTGGTCTG-3\' (complementary to the 1122 nt--- 1142 nt region from the 5\'-terminus) for the vRNA of segment 5; 5\'-TCATCTTTGTTCCTCAA-3\' (3\' terminal region) for the cRNA of segment 5; and oligo-dT20 (5\'-TTTTTTTTTTTTTTTTTTTT-3\') for the viral mRNA. The RT reactions were performed using the hot-start protocol as described elsewhere ([@bib21]). Total RNA (50--100 ng) and the aforementioned specific primer (10 pmol) were heated in a volume of 5.5 μl at 65°C for 5 min, chilled immediately in an ice-water bath, and then preincubated at 48°C. The RT premixture (3 μl First Strand buffer \[5×, Invitrogen, Carlsbad, CA\]; 0.75 μl of 0.1 M DTT; 0.75 μl of 10 mM dNTP mixture; 0.25 μl of Superscript III Reverse Transcriptase \[200 U/μl, Invitrogen\]; 0.25 μl RNase inhibitor; and 4.5 μl of saturated trehalose \[Sigma\] in a total of 9.5 μl) was also preincubated at 48°C and quickly added to the RNA-primer mixture and incubated at 48°C for 1 hr. The RT reaction mixture was diluted ten-fold with H~2~O and incubated at 95°C to terminate the RT reaction. The diluted cDNA sample (3 μl) was subjected to quantification by real-time PCR using the FastStart SYBR Green Master (Roche) and the segment 5-specific primer set (5 pmol each/15 μl of the qPCR reaction mix), 5'-GACGATGCAACGGCTGGTCTG-3\' and 5'-AGCATTGTTCCAACTCCTTT-3\'. Real-time PCR was performed using the Thermal Cycler Dice Real Time System TP800 (Takara, Japan).

Growth curve analysis {#s4-7}
---------------------

Growth curve analysis was performed by infecting confluent A549 cells (96 hr after transfection of siRNA) in 35-mm dishes with FluV/A/WSN/33 virus at an MOI of 0.001 and harvesting the supernatant every 12 hr after infection for 60 hr. The virus titers present in the supernatant were determined by a standard plaque assay using MDCK cells.

Plasmid constructions {#s4-8}
---------------------

Full-length cDNA of human IREF-2α/pp32 was amplified using KOD polymerase (Toyobo) from a cDNA library prepared from HeLa cell mRNA using the specific primers 5\'-CGCGGATCCCATATGGAGATGGGCAGACGGATTCATTTAG-3\' and 5\'-GCGGCTCGAGACGTCAGTCATCATCTTCTCCCTCATCTTCAGGTTCTCGT-3\', corresponding to the pp32 amino-terminal and carboxyl-terminal regions, respectively. The full-length cDNA of human IREF-2β/APRIL was also amplified by using the specific primers 5\'-CGGAATTCATATGGACATGAAGAGGAGGATCCACCTGGAG-3\' and 5\'-GCGGCTCGAGACGTCAATCATCTTCTCCTTCATCATCTGT-3\', corresponding to the APRIL amino-terminal and carboxyl-terminal regions, respectively. To construct the glutathione *S*-transferase (GST)-tagged pp32 expression vectors for *Escherichia. coli* cells (pGEX-2T-pp32), the amplified cDNA fragment of pp32 was digested with *Bam*HI and *Aat*II and then cloned into pGEX-2T (GE Healthcare) predigested with the same restriction enzymes. To construct *E. coli* expression vectors for GST-tagged APRIL (pGEX-2T-APRIL), the amplified cDNA fragment of APRIL was digested with *Eco*RI and *Aat*II and then cloned into pGEX-2T predigested with the same restriction enzymes. To construct mammalian expression vectors expressing GST harboring the nuclear localization signal (NLS) at the C-terminal end, termed pCAGGS-GSTnls, DNA fragments were amplified by PCR using the specific primer set 5\'-CCCTCGAGCTCGCG[GCCGCCGCC]{.ul}ATGGGCTCCCCTATACTAGGTTATTGG-3\' (the sequence responsible for the 'Kozak translational consensus' is underlined) and 5'-AAGATCTATGCATGGTACCGCTAGCGACGTCACCCGGGGTCTTCTACC-3\', and pGEX-2T-SV40 NLS-GFP (kindly gifted by Dr Yoneda, Osaka University) as the PCR template. The PCR products corresponding to Kozak-GSTnls were trimmed by digestion with *Xho*I and *Bgl*II and then cloned into the predigested pCAGGS mammalian expression vector, resulting in pCAGGS-GSTnls. To construct mammalian expression vectors expressing GST-tagged IREF-2s, pGEX-2T-pp32 and pGEX-2T-APRIL were digested with *Swa*I (for cutting within the GST coding region) and *Aat*II (for cutting downstream of the termination codon of both IREF2s), and each DNA fragment corresponding to GST~C-term~-IREF-2 was subcloned into the pCAGGS-GSTnls predigested with *Swa*I and *Aat*II, resulting in pCAGST-pp32 and pCAGST-APRIL. To construct pCAGST-RAF2p48 expressing GST-fused RAF2p48/BAT1/UAP56, a DNA fragment corresponding to the GST-RAF2p48-encoding region derived from pGEX-p48 was subcloned into the pCAGGS vector, resulting in pCAGST-RAF2p48. The nucleotide sequences of all plasmids constructed for this study were confirmed by DNA sequencing (ABI prism genetic analyzer; Applied Biosystems, Foster City, CA).

Preparation of recombinant IREF-2 proteins {#s4-9}
------------------------------------------

To express recombinant IREF-2 proteins, *E. coli* BL21(DE3) cells harboring the expression vectors (pGEX-2T-pp32 and pGEX-2T-APRIL) for GST-tagged IREF-2s were cultivated at 30°C until A590 reached 0.5, and protein production was then induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside for 6 hr. The induced cells were harvested by centrifugation and resuspended in a lysis buffer (50 mM Hepes-NaOH \[pH 7.9\], 150 mM KCl, 0.25% NP-40, and 1 mM DTT) and sonicated well in an ice-water bath. The insoluble material was removed by centrifugation, and crude extracts were recovered as a supernatant fraction was applied to Glutathione-Sepharose 4B resin that had been equilibrated with the lysis buffer. After capturing of the GST-tagged proteins to the resin, lysis buffer was applied to wash away the unbound materials. The washed resins were equilibrated with a digestion buffer (50 mM Hepes-NaOH \[pH 7.9\], 50 mM KCl, 1 mM CaCl~2~, and 1 mM DTT) and digested with thrombin (Nacalai Tesque) at 4°C overnight. The materials with the GST portion removed were collected and further purified through a Mono-Q column with KCl linear gradient elution. The purified proteins were dialyzed with buffer H containing 1 mM DTT, and the concentration of each protein was determined by the Bradford method and comparison of band intensities with a standard protein (BSA) after separation by SDS-PAGE.

Transfection of DNA and siRNA and virus infection {#s4-10}
-------------------------------------------------

For transfection of HEK293T cells with mammalian expression plasmids, plasmid DNA mixtures were prepared in Opti-MEM (Thermo Fisher Scientific, Waltham, MA), and an appropriate amount of PEI (Sigma Aldrich, St. Louis, MO) were mixed into the DNA solution (1.5 μg PEI per 1 μg DNA) and incubated at room temperature for 10 min. The DNA/PEI complex was added to monolayer cell cultures (approximately, 3 × 10^6^ cells in a 100-mm-diameter dish). Six hours after transfection, the medium was replaced with fresh DMEM and maintained at 37°C.

For transfection of siRNAs, trypsinized cells (HeLa, HEK293T, and A549) were seeded, and pp32 siRNA (custom-designed Stealth RNAi; Invitrogen), APRIL siRNA (ANP32B-HSS116202; Invitrogen), and negative control siRNA (12935--200; Invitrogen) were introduced into the cells with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer\'s protocol. Twelve to twenty-four hours after the first transfection, the cells were again transfected with the same amount of siRNA used at the first transfection and maintained at 37°C for 4 to 5 days until influenza virus infection.

For virus infection, monolayer cultures of human cells (HEK293T, HeLa, and A549) were washed with serum-free MEM, and the cells were infected with influenza A/PR/8 virus allantoic fluid at the desired MOI as described in each figure legend. After virus adsorption at 37°C for 1 hr, the infecting allantoic fluid was removed, and the cells were washed with serum-containing medium and maintained at 37°C in the medium for an appropriate period (3--9 hr).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"pp32 and APRIL are host cell-derived regulators for the influenza virus vRNA synthesis from cRNA\" for peer review at *eLife*. Your submission has been favorably evaluated by Detlef Weigel (Senior Editor), a Reviewing Editor, and three reviewers, one of whom is a member of our Board of Reviewing Editors. One of the three reviewers, Andrew Mehle (Reviewer \#2), has agreed to reveal his identity.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

While all the reviewers were excited by the findings, there were several perceived weaknesses in the story, and additional work was universally asked for. What was most critically needed was the inclusion of better indications of the importance of these factors in cells. Very specific experiments were proposed in the reviews, and adding new data that proved the roles of these proteins in replication, and in the expected steps of replication, is essential.

Reviewer \#1:

Influenza RNA replication, distinct from mRNA synthesis, involves the synthesis of cRNA (RNA complementary to the genome) first, and then vRNAs (viral RNA, minus-strand). Both cRNA and vRNA have 5\' triphosphate ends such that both are initiated de novo, not via cap-snatching as in transcription. This paper reports the identification of two cellular proteins that act to stimulate influenza RNA-dependent RNA polymerase (made up of PB1, PB2, and PA), specifically to increase the second step of replication, the synthesis of new vRNA from cRNA, as assayed in reactions on short templates in vitro. The products were confirmed to have appropriate sense and 5\' triphosphate ends. The proteins with this activity were identified as pp32 and APRIL. Both had been found in other proteomic or functional screens. The proteins were confirmed to only stimulate vRNA and not cRNA synthesis. Both were shown to bind vRdRP (and only as a trimeric complex) and not the viral protein NP. KD led to small reductions in viral RNA levels in vivo.

This work is of interest as identifying strand-specific initiation factors for influenza replication. The in vitro stimulation assays, the MS identification, and the assays of the recombinant proteins seem adequate, notably the strand specificity. The binding to the trimer also seems convincing and is an interesting result. The paper provides a significant and useful addition to the field.

Concerns:

It would be helpful to know if these factors bind to RNA first and then vRdRP or the other way around. Can they bind and protect the 3\' ends of the template?

The knockdowns show only modest effects on viral RNA levels and the CHX experiments are particularly unconvincing. Thus the importance of the factors in vivo is not certain. Better experiments in this area would be helpful.

Reviewer \#2:

The influenza polymerase synthesizes viral genomic and messenger RNA in a temporally coordinated fashions. How vRNA, cRNA and mRNA production is regulated, and the co-factors that do this, is an area of significant interest. Sugiyama, et al. identify APRIL and pp32 as host proteins that regulate polymerase function. Their biochemistry nicely shows that APRIL/pp32 exclusively stimulate vRNA synthesis from a cRNA template in vitro. Nonetheless, the authors lack cell-based data showing that these proteins function in the same way as physiologically relevant regulators during viral infection.

1\) The in vitro biochemistry is fairly convincing and shows that APRIL/pp32 stimulate vRNA synthesis from a model cRNA template. These finds are never validated in cells, raising multiple questions:

a\) There are no data describing the effect of APRIL/pp32 knockdown on virus replication. Do these co-factors function during the full viral life cycle (e.g. single- or multi-cycle replication) and in the context of a real cRNP?

b\) Knockdown of APRIL/pp32 reduces all viral RNA products during infection, as opposed to their in vitro data showing APRIL/pp32 only stimulate vRNA synthesis. Controls show that mRNA production is unchanged, but they could not test cRNA vs vRNA in the knockdown cells. As the major claim of their paper is that APRIL/pp32 stimulate cRNA synthesis, this discrepancy between their results in vitro and in cells during infection needs to be addressed experimentally. Perhaps investigating the role of APRIL/pp32 on purified cRNPs (following techniques from York et al., 2013), or when using a cRNA reporter, could help address these gaps.

c\) Do APRIL/pp32 only affect vRNA synthesis in cells, or might they stimulate svRNAs? This is important to differentiate in cells as both vRNA and svRNA are produced from the same template by the same polymerase, and svRNAs have been implicated in shifting the polymerase towards synthesizing vRNA (just as the authors\' APRIL/pp32 factors do). All of the gels for their in vitro assays are cropped, so it is not possible to know if svRNAs are produced in vitro.

2\) Binding experiments in [Figure 4](#fig4){ref-type="fig"} were all done in cells over-expressing transfected APRIL/pp32. Experiments demonstrating binding between the polymerase and endogenous APRIL/pp32 are needed to determine if these interactions are biologically relevant.

Reviewer \#3:

Using cell-free influenza polymerase derived by micrococcal nuclease treated vRNPS purified from virions the authors are unable to detect unprimed vRNA synthesis using a 53-mer cRNA template, whereas ApG primed synthesis of vRNA is observed. They are able to purify a fraction of nuclear extract from uninfected HeLa cells that promotes unprimed vRNA synthesis, but not unprimed cRNA synthesis from a vRNA template. The active host proteins are identified by mass-spec as APRIL and pp32 and the effect is recapitulated with purified recombinant APRIL and pp32. These proteins are homologous, have independent and additive stimulatory activity and have previously been identified as influenza polymerase interacting proteins. They are shown to only bind to the trimeric polymerase, preferably in the \'free state\' (i.e. not part of an RNP). Finally the authors show that siRNA knockdown of APRIL or pp32 or both in HeLa cells with subsequent infection by influenza virus leads to significantly reduced levels of all viral RNAs, vRNA, cRNA and mRNA, compared to the control infection without knockdown. The authors conclude that APRIL and pp32 promote viral replication by stimulating unprimed vRNA synthesis from cRNA.

This study raises a number of questions:

1\) The source of polymerase the authors used is micrococcal nuclease treated vRNPs purified from virions. This is a poorly characterized, presumably heterogeneous sample. It is not clear, and should be stated, if any purification is done after stopping the nuclease digestion with 3 mM EGTA. Is the nuclease and EGTA still present in downstream experiments? One can imagine the preparation is highly heterogeneous containing free polymerase, polymerase bound to the conserved 3\' and 5\' ends (which are protected from nuclease), nucleoprotein bound to RNA fragments, free nucleoprotein, etc. All these things could influence the fate of added cRNA or vRNA template in an artifactual way (e.g. free NP sequestering template RNA, etc.). The authors should in the main text discuss what they think the preparation really contains.

2\) Is this polymerase preparation capable of doing cap-dependent transcription e.g. upon adding capped RNA? If not, why not? If it can, then the effect of APRIL and pp32 on transcription could have been tested in vitro.

3\) As the authors discuss in the Discussion, un-primed vRNA-synthesis was previously demonstrated in the absence of exogenously added primer or host factors by other authors using different preparation methods of polymerase. In contrast, Sugiyama et al. do not detect any vRNA-synthesis under their experimental conditions and in the absence of RNA-primer or host-proteins. However, as the authors point out, reaction-conditions like the reaction-time or particularly the enzyme-concentration, might affect the results and conclusions. To compare data from individual experiments and laboratories, it would be beneficial to determine (and not just discuss in the Discussion) the (estimated) active enzyme-concentration used in the experiments and/or vary parameters, in particular the reaction-time to perhaps overcome some detection limits.

4\) Irrespective of the above, the authors come up with APRIL and pp32 as putative host factors that enhance vRNA synthesis, consistent with other recent work that identifies these proteins as polymerase associated host factors. The critical experiment is then the demonstration of this activity in infected cells. However the authors only show that siRNA knockdown of APRIL or pp32 or both in HeLa cells with subsequent infection by influenza virus leads to significantly reduced levels of all viral RNAs, vRNA, cRNA and mRNA. They argue that this is consistent with a specific role of APRIL and pp32 in being required for enhancing vRNA synthesis (which then has a knock on effect on other viral RNAs) but there is no direct proof that this is the mechanism in infected cells (except that they show there is no clear affect directly on primary transcription). For clarity and consistency the authors should also show growth curves for virus in knockdown and control cells and repeat these experiments in one other more relevant cell line (HeLA cells are very particular).

5\) The authors propose that the mechanism for enhanced vRNA synthesis could be related to the different mode of initiation of vRNA synthesis, which has been reported to involve internal initiation and then realignment. Yet in an infected cell vRNA synthesis occurs in the context of a cRNP particle, whereas the authors argue that APRIL and pp32 preferably binds free polymerase. But free polymerase does not do RNA synthesis so how can APRIL and pp32 bound to free polymerase influence an initiation process that occurs buried in the internal cavity of the polymerase which is part of a cRNP? This paradox needs to be further discussed/explained by the authors.

10.7554/eLife.08939.016

Author response

Reviewer \#1:*\[...\] It would be helpful to know if these factors bind to RNA first and then vRdRP or the other way around. Can they bind and protect the 3\' ends of the template?*

To examine whether both IREF-2 proteins, pp32 and APRIL, bind the viral RNA template, we performed the electrophoresis mobility shift assay (EMSA). As shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, the interaction between each IREF-2 and viral RNA could not be observed. The description for this result has been added in the revised manuscript (subheading "Interaction between IREF-2 and viral RNA polymerases").

The knockdowns show only modest effects on viral RNA levels and the CHX experiments are particularly unconvincing. Thus the importance of the factors in vivo is not certain. Better experiments in this area would be helpful.

Possible reasons for such "modest effects on viral RNA levels" by the knockdown observed in [Figure 5B](#fig5){ref-type="fig"} had been already explained in the Discussion section of the original manuscript and the revised manuscript. We cannot agree with the comment "the CHX experiments are particularly unconvincing", because the result is statistically clear ([Figure 5C](#fig5){ref-type="fig"}), demonstrating that the primary transcript transcribed only from "incoming vRNP" in the presence of CHX is not affected by IREF-2 knockdown, while the transcription level in the absence of CHX (i.e. the transcript sum of the primary transcription and multi-round transcription from newly replicated vRNA template) was significantly reduced by the knockdown. The effects of the knockdown on the transcripts level in the presence or absence of CHX condition were verified by student's t test.

As "better experiments in this area", growth curve experiments were also carried out, and significant defect in progeny virus production could be observed by knockdown of IREF-2. This result was represented as [Figure 5D](#fig5){ref-type="fig"} in the revised manuscript, and explained in paragraph three, subheading "Effect of IREF-2 on viral RNA synthesis in infected cells" in the revised manuscript.

Reviewer \#2:*1) The in vitro biochemistry is fairly convincing and shows that APRIL/pp32 stimulate vRNA synthesis from a model cRNA template. These finds are never validated in cells, raising multiple questions:*

*a) There are no data describing the effect of APRIL/pp32 knockdown on virus replication. Do these co-factors function during the full viral life cycle (e.g. single- or multi-cycle replication) and in the context of a real cRNP?*

The results shown in [Figures 5B,C](#fig5){ref-type="fig"} clearly demonstrated that IREF-2s play a role in replication, but not in transcription process. As pointed out here, the effect of IREF-2 on the "multi-cycle replication" was examined by growth curve experiments, and significant defect in progeny virus production could be observed by knockdown of IREF-2. This result was newly added as [Figure 5D](#fig5){ref-type="fig"} in the revised manuscript, and explained in paragraph three, subheading "Effect of IREF-2 on viral RNA synthesis in infected cells".

*b) Knockdown of APRIL/pp32 reduces all viral RNA products during infection, as opposed to their in vitro data showing APRIL/pp32 only stimulate vRNA synthesis. Controls show that mRNA production is unchanged, but they could not test cRNA vs vRNA in the knockdown cells. As the major claim of their paper is that APRIL/pp32 stimulate cRNA synthesis, this discrepancy between their results in vitro and in cells during infection needs to be addressed experimentally. Perhaps investigating the role of APRIL/pp32 on purified cRNPs (following techniques from York et al., 2013), or when using a cRNA reporter, could help address these gaps.*

According to the comment, the method for cRNP isolation suggested by this reviewer (York etal., 2013) was too difficult to establish in our hands during this revision period. Instead, we tried to distinguish the effect of IREF-2 on vRNA and cRNA syntheses in vivo using mini-replicon-based influenza virus reporter system as alternatively suggested by this reviewer. Here, vRNA and cRNA of the viral reporter genome (termed as "vNS-Luc" and "cNS-Luc", respectively) were individually supplied using "pPol I-vNS-luciferase vector" and "pPol I-cNS-luciferase vector", respectively ([Author response image 1](#fig6){ref-type="fig"} panel A). At 24 hours after transfection of expression vectors for viral polymerases, NP, and viral reporter genome RNAs into Control knockdown (KD) and IREF-2-double KD 293T cells, the accumulation levels of vRNA, cRNA, and mRNA from the viral reporter gene were quantitatively determined by RT-qPCR ([Author response image 1](#fig6){ref-type="fig"}, panel B, also included in the manuscript as [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).10.7554/eLife.08939.013Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.013](10.7554/eLife.08939.013)

The viral reporter RNA levels of 3 species in this experiment were significantly decreased by IREF-2 KD as observed in infected IREF-2 KD cells ([Figure 5B](#fig5){ref-type="fig"}). In the case of vNS-luciferase as a source of the viral genome (Panel B, left panel), the vRNA level appears to be more decreased by IREF-2 KD (12% of control) compared with the reduction of the cRNA level (23% of control). Based on the assumption that IREF-2 stimulates preferentially vRNA synthesis rather than cRNA synthesis, it is expected that the vRNA level is to be more reduced by IREF-2 KD than the cRNA level in these experiments. Meanwhile, all viral RNA levels were shown decreased almost comparably (46%-48% reductions) in the case of cNS-luciferase used as a source of the viral genome ([Author response image 1](#fig6){ref-type="fig"}, panel B, right panel). We consider that a convincing difference in the reduction level of between vRNA and cRNA could not be observed enough to distinguish the effects of IREF-2 KD on vRNA and cRNA syntheses in these reporter experiments. The stimulation effect of IREF-2 could be observed only in the case of unprimed vRNA synthesis in in vitro experiments as shown in [Figure 3](#fig3){ref-type="fig"}, while both vRNA and cRNA (and also mRNA) levels were decreased comparably by IREF-2 KD in in vivo experiments ([Figure 5B](#fig5){ref-type="fig"}, and also [Author response image 1](#fig6){ref-type="fig"} shown above). A possibility for why vRNA and cRNA syntheses cannot be distinguished each other in infected cells had already been explained in the Results section (subsection "Effect of IREF-2 on viral RNA synthesis in infected cells"), as follows: vRNA serves as a template for cRNA synthesis, and vice versa. Therefore, if vRNA synthesis is impaired, cRNA synthesis (and also mRNA synthesis) is affected due to interdependency. This theoretically correct explanation has been already observed in a previous study (Maier et al.; Virology 370, 194-204, 2006). In their study, certain site-directed mutants of vRdRP, "T173A" or "F176A" substitution in PA subunit of vRdRP, were shown to have a significant defect only in cRNA template binding, but not vRNA template binding. Due to this selective defect in the template binding property, these vRdRP mutants exhibited significant loss of vRNA synthesis activity from the cRNA template in their cell-free (in vitro) reaction, but cRNA synthesis activity from the vRNA template of the vRdRP mutants was not impaired (see [Figure 5](#fig5){ref-type="fig"} in Maier et al., 2006). In addition, significant reductions of all 3 kinds of viral RNA species (vRNA, cRNA, and viral mRNA) were observed at comparable levels in in vivo experiments using these vRdRP mutants (see [Figure 7](#fig7){ref-type="fig"} in Maier et al., 2006). This previous observation by Maier et al., using vRdRP mutants appears to be similar to our results through depletion of host-derived factors by knockdown (in [Figure 3](#fig3){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}). The previous literatures quoted for above explanation (Maier et al., 2006) were also provided in the revised manuscript (paragraph two, subheading "Effect of IREF-2 on viral RNA synthesis in infected cells") and listed in the References.

The reason for these observations is not clearly explained. At least for mini-replicon system, the system contains the background level of vRNA or cRNA synthesized from vectors by RNA polymerase I. To distinguish vRNA and cRNA synthesis in vivo, another approach would be needed.

*c) Do APRIL/pp32 only affect vRNA synthesis in cells, or might they stimulate svRNAs? This is important to differentiate in cells as both vRNA and svRNA are produced from the same template by the same polymerase, and svRNAs have been implicated in shifting the polymerase towards synthesizing vRNA (just as the authors\' APRIL/pp32 factors do). All of the gels for their in vitro assays are cropped, so it is not possible to know if svRNAs are produced in vitro.*

Small leader vRNA (svRNA) is 22-27 nucleotide-long RNA from 5'-terminal region of vRNA and known to be important for the regulation of vRNA replication, as mentioned by this reviewer. This has already been taken into account and described in the Discussion section in the original manuscript and also in the revised manuscript. In addition, according to the comment, we tried to address the possibility that the production of svRNA is also regulated by IREF-2. As shown in the figure below ([Author response image 2](#fig7){ref-type="fig"}), not only full-length RNA product (53 nt) but also short RNA products (\~25 nt; termed as "Short products 2") could be observed by adding recombinant pp32 to the cell-free reaction, suggesting the possibility that svRNA production is also stimulated by IREF-2.10.7554/eLife.08939.014Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.08939.014](10.7554/eLife.08939.014)

2\) Binding experiments in [Figure 4](#fig4){ref-type="fig"} were all done in cells over-expressing transfected APRIL/pp32. Experiments demonstrating binding between the polymerase and endogenous APRIL/pp32 are needed to determine if these interactions are biologically relevant.

According to this comment, the interaction between viral polymerases (vRdRP) and endogenous IREF-2 proteins were examined. It is confirmed that both endogenous IREF-2 proteins (pp32 and APRIL) interact with the vRdRP trimeric complex. This result is represented as [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, and explained in the revised manuscript (paragraph two, "Interaction between IREF-2 and viral RNA polymerases").Reviewer \#3:*1) The source of polymerase the authors used is micrococcal nuclease treated vRNPs purified from virions. This is a poorly characterized, presumably heterogeneous sample. It is not clear, and should be stated, if any purification is done after stopping the nuclease digestion with 3 mM EGTA. Is the nuclease and EGTA still present in downstream experiments? One can imagine the preparation is highly heterogeneous containing free polymerase, polymerase bound to the conserved 3\' and 5\' ends (which are protected from nuclease), nucleoprotein bound to RNA fragments, free nucleoprotein, etc. All these things could influence the fate of added cRNA or vRNA template in an artifactual way (e.g. free NP sequestering template RNA, etc.). The authors should in the main text discuss what they think the preparation really contains.*

This mnRNP preparation method has been established in over 20 years ago (Seong and Brownlee; Virology 186, 247-260, 1992), and well characterized by their studies and following studies. Fundamental properties of the mnRNP activity in the presence or absence of primer, and with vRNA or cRNA template characterized in the previous report (see [Figure 7](#fig7){ref-type="fig"} in Seong and Brownlee, 1992) and our study (see lanes 1, 2, 6 and 7 in [Figure 3B](#fig3){ref-type="fig"}) were completely the same.

At least, MNase and EGTA present in the mnRNP preparation seem not to exert an inhibitory influence on the viral RNA synthesis in cell-free system: in a previous report (Seong et al.; J. Biochem. 111, 496-499, 1992), 2 kinds of virion-derived enzyme sources, mnRNP (termed as "MN enzyme" in their report) and MNase/EGTA-free CsCl-RNP (termed as "CS enzyme"), were compared each other. There was no significant difference in the property of the vRdRP activity between these two enzyme sources (see [Figure 1B](#fig1){ref-type="fig"} in Seong et al., 1992). This strongly suggests that MNase and EGTA used for the mnRNP preparation have no influence on the enzymatic activity. In addition, the heterogeneity of the vRdRP in mnRNP has been taken account in the previous reports (Seong and Brownlee; Virology 186, 247-260, 1992). The vRdRP with residual 3'- and 5'- terminal parts of the viral genome RNA (vRNA) protected from MNase digestion, can be detected as 14-21 nt-long short RNA products in a previous report (Seong and Brownlee, 1992) and also in our hands. Therefore, such short by-products can be easily distinguished from 53 nt long objective products synthesized from the exogenously added viral model RNA templates (i.e. "v53" and "c53") used in this study. Related to these issues described above, brief explanation about mnRNP was added in the Results section (subheading "Purification of IREF-2 from nuclear extracts of uninfected cells"), and the previous literatures quoted for above explanation were also referred there and listed in the References.

On the other hand, the effect of NP involved in the mnRNP preparation is relatively uncertain. However, the possibility mentioned in this comment that free NP sequesters the viral RNA template can be ruled out due to the fact that robust ApG-primed RNA products were synthesized from the exogenously-added viral template even in the presence of the same amount of NP present in the mnRNP preparation used for our experiments (see lanes 1 and 6 in [Figure 3B](#fig3){ref-type="fig"}). The explanation about the influence of NP in the mnRNP preparation was added in the Discussion section (paragraph three). The relationship between IREF-2 (pp32 and APRIL) and NP is not addressed in this study. Therefore, the possibility that NP is requisite for the IREF-2 regulation in vRNA replication process should be taken into acount, and this seems to be addressed by the cell-free viral RNA synthesis system using NP-free enzyme source such as recombinant vRdRP. These points are discussed in the Discussion section (paragraph three) in the revised manuscript.

2\) Is this polymerase preparation capable of doing cap-dependent transcription e.g. upon adding capped RNA? If not, why not? If it can, then the effect of APRIL and pp32 on transcription could have been tested in vitro.

The enzyme source, mnRNP, used in our study is fully capable of the cap-dependent transcription, and according to this comment, cell-free viral transcription assay was performed. The result is newly represented as [Figure 3D](#fig3){ref-type="fig"} and explained in the revised manuscript (paragraph three, subheading "Identification of pp32 and APRIL as IREF-2"). IREF-2 (pp32) gave no effect on the cap-dependent (cap-snatching) transcription in cell-free (in vitro) reaction (see [Figure 3D](#fig3){ref-type="fig"} lanes 3-5 in the revised manuscript). This observation is consistent with the result obtained in infected cells (in vivo) as shown in [Figure 5C](#fig5){ref-type="fig"}, which demonstrated that primary transcription from incoming vRNP was not affected by IREF-2 knockdown.

3\) As the authors discuss in the Discussion, un-primed vRNA-synthesis was previously demonstrated in the absence of exogenously added primer or host factors by other authors using different preparation methods of polymerase. In contrast, Sugiyama et al. do not detect any vRNA-synthesis under their experimental conditions and in the absence of RNA-primer or host-proteins. However, as the authors point out, reaction-conditions like the reaction-time or particularly the enzyme-concentration, might affect the results and conclusions. To compare data from individual experiments and laboratories, it would be beneficial to determine (and not just discuss in the Discussion) the (estimated) active enzyme-concentration used in the experiments and/or vary parameters, in particular the reaction-time to perhaps overcome some detection limits.

The enzyme source, mnRNP was established in earlier study and had been well-characterized (Seong and Brownlee; Virology 186, 247-260, 1992). It is known that mnRNP has very weak activity for unprimed cRNA synthesis from vRNA template, but no activity for unprimed vRNA syntheis from cRNA template (Seong and Brownlee, 1992, and Seong et al.; J. Biochem. 111, 496-499, 1992). Such properties are exactly the same as our mnRNP (see lanes 1, 2, 6 and 7 in [Figure 3B](#fig3){ref-type="fig"}). As examined by a previous study (Seong and Brownlee, 1992), any parameters such as reaction-time, amount of mnRNP, pH, temparature, etc., in our cell-free reaction system were optimezed and have been already confirmed to be appropriate condition (Watanabe et al.; J. Virol. 70, 241-247, 1996, and Momose et al.; J. Virol. 75, 1899-1908, 2001).

This reviewer recommended to compare the enzyme sources in the previous reports using recombinant vRdRP and those in this study using mnRNP, but it is practically impossible due to the following reasons: among two previous studies using recombinant vRdRP, the amount of vRdRP used by Deng et al. (J. Virol. 80, 2337-2345, 2006) is unclear due to no information described (only description about the volume of vRdRP used in their reaction). On the other hand, 100 nM of vRdRP prepared using baculovirus expression was used by Zang et al. (J. Biol. Chem. 285, 41194-41201, 2010). However, it is very difficult to set up the reaction using 100 nM of mnRNP in our cell-free reaction due to the limitation of the stock concentration of mnRNP, which is prepared from a large quantity of virions (approximately 10-30 nM of vRdRP in our and other mnRNP stocks). Furthermore, an excess amount of mnRNP in our cell-free reaction system, if possible, is known to exhibit the inhibitory effect on the viral RNA synthesis even in the case of the ApG-primed RNA synthesis (Galarza et al.; J. Virol. 70 2360-2368, 1996). An exact reason for that is uncertain, and it might be plausible that an excess amount of NP accompanied with the addition of large amount of mnRNP in the reaction resulted in the inhibition of the reaction as observed in a previous study by Galarza et al.

In the previous report (Zang et al., 2010), unprimed RNA products were shown to be sythesized at the comparable level of ApG-primed RNA products (see [Figure 1](#fig1){ref-type="fig"} in Zang. et al., 2010), even though the length of their unprimed RNA products were abnormal (3 nt-shorther than template size). In another previous report by Deng et al., (2006), the unprimed and ApG-primed RNA products were shown in different panels, so that it is difficult to compare each other. In our study on the other hand, unprimed RNA products were not detected at all, while robust ApG-primed RNA products were observed (compare lanes 6 and 7 in [Figure 3B](#fig3){ref-type="fig"} in this study).

Collectively, it seems difficult to compare results obtained by fundamentally different conditions. In addition, even for recombinant vRdRP with different enzymatic properties prepared by different laboratories, the difference among them is not completely addressed yet

4\) Irrespective of the above, the authors come up with APRIL and pp32 as putative host factors that enhance vRNA synthesis, consistent with other recent work that identifies these proteins as polymerase associated host factors. The critical experiment is then the demonstration of this activity in infected cells. However the authors only show that siRNA knockdown of APRIL or pp32 or both in HeLa cells with subsequent infection by influenza virus leads to significantly reduced levels of all viral RNAs, vRNA, cRNA and mRNA. They argue that this is consistent with a specific role of APRIL and pp32 in being required for enhancing vRNA synthesis (which then has a knock on effect on other viral RNAs) but there is no direct proof that this is the mechanism in infected cells (except that they show there is no clear affect directly on primary transcription). For clarity and consistency the authors should also show growth curves for virus in knockdown and control cells and repeat these experiments in one other more relevant cell line (HeLA cells are very particular).

According to this comment, growth curve experiments using A549 cell line derived from human alveolar basal epithelium were carried out repeatedly (three times). As a result, significant defect in the progeny virus production and accumulation from IREF-2 knockdown A549 cells can be observed. The result was represented as [Figure 5D](#fig5){ref-type="fig"} in the revised manuscript, and explained and discussed in the Results section (paragraph three, subheading "Effect of IREF-2 on viral RNA synthesis in infected cells").

5\) The authors propose that the mechanism for enhanced vRNA synthesis could be related to the different mode of initiation of vRNA synthesis, which has been reported to involve internal initiation and then realignment. Yet in an infected cell vRNA synthesis occurs in the context of a cRNP particle, whereas the authors argue that APRIL and pp32 preferably binds free polymerase. But free polymerase does not do RNA synthesis so how can APRIL and pp32 bound to free polymerase influence an initiation process that occurs buried in the internal cavity of the polymerase which is part of a cRNP? This paradox needs to be further discussed/explained by the authors.

A complex of IREF-2 with vRdRP in infected cells appears to be template-free as shown in [Figure 4](#fig4){ref-type="fig"}, and ready to bind viral RNA template. cRNA would be recruited to the IREF-2-vRdRP complex (IREF-2-cRNP formation), followed by initiation and elongation of vRNA synthesis reaction. In our interpretation, this IREF-2 protein complexed with cRNP seems to be released from the cRNP complex during vRNA replication process. Therefore, we consider that the interaction between IREF-2-vRdRP and cRNA seems transient, and dissociated IREF-2 might interact with another RNA-free vRdRP again. Thus, the majority of IREF-2-vRdRP complex in infected cells appear to be free of RNA and NP/NP bound to RNA. The explanation according to this reviewer's comment has been already described in the original manuscript and also in the revised version (Discussion).
